Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiko Udaka

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 10, 2019
Identification of a Promiscuous Epitope Peptide Derived From HSP70Hiroto Matsui, Shoichi Hazama, Koji Tamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 17, 2023
Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trialMasao Nakajima, Shoichi Hazama, Yukio Tokumitsu, et al.
Blood|April 20, 2002
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignanciesOlga A Elisseeva, Yoshihiro Oka, Akihiro Tsuboi, et al.
Oncology Reports|March 3, 2018
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptidesShinsuke Kanekiyo, Shoichi Hazama, Hiroko Takenouchi, et al.
Microbiology and Immunology|March 20, 2004
WT1 peptide-based immunotherapy for patients with lung cancer: report of two casesAkihiro Tsuboi, Yoshihiro Oka, Tadashi Osaki, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trialMasao Nakajima, Shoichi Hazama, Koji Tamada, et al.
Japanese Journal of Clinical Oncology|April 14, 2006
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I dataSatoshi Morita, Yoshihiro Oka, Akihiro Tsuboi, et al.
JCI Insight|March 17, 2026
Position-5-Driven Reorientation of an Immunodominant HLA-A*24:02 SARS-CoV-2 Epitope Drives Universal T-cell EscapeTakeshi Nakama, Aaron Wall, Garry Dolton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2004
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regressionYoshihiro Oka, Akihiro Tsuboi, Tetsuya Taguchi, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 10, 2019
Identification of a Promiscuous Epitope Peptide Derived From HSP70Hiroto Matsui, Shoichi Hazama, Koji Tamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 17, 2023
Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trialMasao Nakajima, Shoichi Hazama, Yukio Tokumitsu, et al.
Blood|April 20, 2002
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignanciesOlga A Elisseeva, Yoshihiro Oka, Akihiro Tsuboi, et al.
Oncology Reports|March 3, 2018
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptidesShinsuke Kanekiyo, Shoichi Hazama, Hiroko Takenouchi, et al.
Microbiology and Immunology|March 20, 2004
WT1 peptide-based immunotherapy for patients with lung cancer: report of two casesAkihiro Tsuboi, Yoshihiro Oka, Tadashi Osaki, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2020
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trialMasao Nakajima, Shoichi Hazama, Koji Tamada, et al.
Japanese Journal of Clinical Oncology|April 14, 2006
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I dataSatoshi Morita, Yoshihiro Oka, Akihiro Tsuboi, et al.
JCI Insight|March 17, 2026
Position-5-Driven Reorientation of an Immunodominant HLA-A*24:02 SARS-CoV-2 Epitope Drives Universal T-cell EscapeTakeshi Nakama, Aaron Wall, Garry Dolton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2004
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regressionYoshihiro Oka, Akihiro Tsuboi, Tetsuya Taguchi, et al.
Pageof 5